Pregled bibliografske jedinice broj: 573109
Alzheimer's Disease: is quetiapine good choice in treatment of psychotic episode
Alzheimer's Disease: is quetiapine good choice in treatment of psychotic episode // XIII World Congress of Psychiatry - 5000 years of science and care - Building the future of psychiatry - Abstracts book / World Psychiatric association, Egyptian Psychiatric Association (ur.).
Kairo: World Psychiatric association, Egyptian Psychiatric Association, 2005. str. 528-528 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 573109 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Alzheimer's Disease: is quetiapine good choice in treatment of psychotic episode
Autori
Uzun, Suzana ; Folnegović-Šmalc, Vera ; Jukić, Vlado ; Mimica, Ninoslav ; Kozumplik, Oliver
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
XIII World Congress of Psychiatry - 5000 years of science and care - Building the future of psychiatry - Abstracts book
/ World Psychiatric association, Egyptian Psychiatric Association - Kairo : World Psychiatric association, Egyptian Psychiatric Association, 2005, 528-528
Skup
XIII World Congress of Psychiatry
Mjesto i datum
Kairo, Egipat, 10.09.2005. - 15.09.2005
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Alzheimer disease; quetiapine; psychotic episode
Sažetak
Objective: to present results of the investigation of the efficacy of quetiapine in patients with Alzheimer's disease, after nine weeks of treatment of psycho- tic episode. Methods: the research comprised 19 patients (9 male and 10 female), with Alzheimer's disease, according to the DSM-IV-TR diagnostic criteria. At baseline, all patients were inpatients. Daily dosage was between 100-300 mg. The Clinical Global Impression (CGI) and the Positive and Negative Syndrome Scale (PANSS) were used in order to assess efficacy of quetiapine treatment. The first assessment was made prior to initiation of quetiapine treatment. The second assessment was made after six weeks, and the third assessment was made after nine weeks of continuous therapy with quetiapine. Results were statistically analyzed using methods of descriptive statistics and chi-square test. Results: six weeks of continuous therapy with quetiapine resulted with significant decrease in PANSS scale, as well as nine weeks of continuous therapy with quetiapine. In the same time, statistically significant improvement was found on CGI. Conclusion: quetiapine was a good choice for the treatment of psychotic epi¬sode in the patients with Alzheimer's disease. Bibliographic References: 1. Uzun S, Folnegović-Šmalc V, Mimica N, Vilibić M, Kozumplik O (2004): Brief psychiatry rating scale and Clinical global impressions in evaluation of symptoms in schizophrenic patients taking typical and atypical antipsychotics. Schizophrenia Res. 67(1): 151. 2. Kozumplik O, Folnegović-Šmalc V, Jukić V, Mimica N, Uzun S (2004): Quality of life in patients with paranoid schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Res. 67(1): 228.
Izvorni jezik
Engleski
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče
Profili:
Ninoslav Mimica
(autor)
Oliver Kozumplik
(autor)
Suzana Uzun
(autor)
Vera Folnegović-Šmalc
(autor)
Vlado Jukić
(autor)